

Complete Listing of the Claims:

1 – 79. (canceled)

80. (currently amended) A method of treating a clinical condition associated with increased activity of kallikrein, plasmin or Factor XIIa, ~~one or more serine proteases~~, comprising administering to a patient suffering from said clinical condition an effective amount of a pharmaceutical composition comprising the following polypeptide: ~~a polypeptide selected from at least one of the following sequences:~~

~~(DD103) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:130)~~
~~(DD104) EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:131)~~
~~(DD105) EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:132)~~
~~(TW6182) EVVREVCSEQAETGPCRAMIHRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:134)~~
~~(TW6194) EVVREVCSEQAETGPCRAMIERWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:135)~~
~~(DD185) EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:171)~~
~~(TW6165) EVVREVCSEQAETGPCRAAIWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:172)~~
~~(TW6166) EVVREVCSEQAETGPCRAAIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:173)~~
~~(BG028) EVVREVCSEQAETGPCRALIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:174)~~
~~(TW6175) EVVREVCSEQAETGPCRALIFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:177)~~
~~(TW6201) EVVREVCSEQAETGPCRAGIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:178)~~
~~(TW6202) EVVREVCSEQAETGPCRAGIWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:179)~~
~~(DD114) EVVREVCSEQAETGPCRAAISRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:183)~~
~~(TW6183) EVVREVCSEQAETGPCRAMHFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:185)~~
~~(TW6184) EVVREVCSEQAETGPCRAMHYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:186)~~
~~(TW6185) EVVREVCSEQAETGPCRAMHWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:187)~~
~~(BG003) EVVREVCSEQAETGPCRAMLHRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:188)~~
~~(TW6187) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:190)~~
~~(TW6188) EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:191)~~
~~(TW6189) EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:192)~~
~~(DD115) EVVREVCSEQAETGPCRGYITRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:194)~~
~~(TW6176) EVVREVCSEQAETGPCRAAHFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:196)~~
~~(TW6177) EVVREVCSEQAETGPCRALHFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:197)~~
~~(BG006) EVVREVCSEQAETGPCRAALFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:198)~~
~~(DD130) EVVREVCSEQAETGPCRALFTRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:199)~~
~~(BG014) EVVREVCSEQAETGPCRALIWHWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:204)~~
~~(DD122) EVVREVCSEQAETGPCRALIFAWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:205)~~
~~(BG015) EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:206)~~
~~(BG020) EVVREVCSEQAETGPCRAAIHKWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:207)~~

(BG022)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMVCGSAI (SEQ ID NO:208) .
~~(BG024)EVVREVCSEQAETGPCRALIYKWFYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:210)~~
~~(DD116)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:212)~~
~~(TW6191)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:213)~~
~~(BG029)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:215)~~
~~(BG030)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:216)~~
~~(BG033)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMVCGSAI (SEQ ID NO:217)~~
~~(BG034)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:218)~~
~~(BG040)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:219)~~
~~(BG025)EVVREVCSEQAETGPCRGLIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:223)~~
~~(BG026)EVVREVCSEQAETGPCRGAIIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:224)~~

81. (currently amended) A method for inhibiting activity of kallikrein, plasmin or Factor XIIa ~~at least one serine protease~~ in a mammal comprising administering a therapeutically effective dose of a pharmaceutical composition, together with a pharmaceutically acceptable sterile vehicle, wherein said composition comprises the following peptide: a polypeptide selected from at least one of the following sequences:

~~(DD103)EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:130)~~
~~(DD104)EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:131)~~
~~(DD105)EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:132)~~
~~(TW6182)EVVREVCSEQAETGPCRAMIHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:134)~~
~~(TW6194)EVVREVCSEQAETGPCRAMIERWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:135)~~
~~(DD185)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:171)~~
~~(TW6165)EVVREVCSEQAETGPCRAAIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:172)~~
~~(TW6166)EVVREVCSEQAETGPCRAAIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:173)~~
~~(BG028)EVVREVCSEQAETGPCRALIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:174)~~
~~(TW6175)EVVREVCSEQAETGPCRALIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:177)~~
~~(TW6201)EVVREVCSEQAETGPCRAGIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:178)~~
~~(TW6202)EVVREVCSEQAETGPCRAGIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:179)~~
~~(DD114)EVVREVCSEQAETGPCRAAISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:183)~~
~~(TW6183)EVVREVCSEQAETGPCRAMHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:185)~~
~~(TW6184)EVVREVCSEQAETGPCRAMHYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:186)~~
~~(TW6185)EVVREVCSEQAETGPCRAMHWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:187)~~
~~(BG003)EVVREVCSEQAETGPCRAMLHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:188)~~
~~(TW6187)EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:190)~~
~~(TW6188)EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:191)~~
~~(TW6189)EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:192)~~
~~(DD115)EVVREVCSEQAETGPCRGYITRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:194)~~

(TW6176)EVVREVCSEQAETGPCRAAHFRWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:196)
(TW6177)EVVREVCSEQAETGPCRALHFRWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:197)
(BG006)EVVREVCSEQAETGPCRAALFRWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:198)
(DD130)EVVREVCSEQAETGPCRALFTRWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:199)
(BG014)EVVREVCSEQAETGPCRALIWHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:204)
(DD122)EVVREVCSEQAETGPCRALIFAWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:205)
(BG015)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:206)
(BG020)EVVREVCSEQAETGPCRAAIHKWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:207)
(BG022)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNNRNNFDTEEHCMVCGSAI (SEQ ID NO:208)
(BG024)EVVREVCSEQAETGPCRALIYKWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:210)
(DD116)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:212)
(TW6191)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYCGCYGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:213)
(BG029)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:215)
(BG030)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:216)
(BG033)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEHCMVCGSAI (SEQ ID NO:217)
(BG034)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:218)
(BG040)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:219)
(BG025)EVVREVCSEQAETGPCRGLIYHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:223)
(BG026)EVVREVCSEQAETGPCRAIYHWYFDVTEGKCAPFFYCGCCGNNRNNFDTEEYCMVCGSAI (SEQ ID NO:224)